[1] European Medicine Agency. Committee for Medicinal Products for Human Use. Assessment report: Xadago [EB/ OL]. [2014-12-18].
http://www.ema.europa.eu/docs/enGB/document library/EPAR-Public assessment report/ human/002396/WC500184967.pdf
[2] 陈其龙, 徐美华, 董文心. 帕金森病治疗药物的临床应用进展[J]. 世界临床药物, 2011, 32(6): 324—328.
[3] 邢瑞娟, 律 涛, 刘磊娜等. 沙芬酰胺的合成[J]. 中国医药工业杂志, 2012, 43(3): 161—163.
[4] Elena B, Laura F, Patricia S, et al. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propan amides with high purity degree: WO, 2009074478 [P] . 2009-06-18.
[5] Pevarello P, Bonsignori A, Dostert P, et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)- amino]-alkanamide derivatives [J]. J Med Chem, 1998,41(4): 579—590.
[6] Reddi A, Muj ahid M, Sa s ikuma r M, e t al . A new enantioselective synthesis of the anti-parkinson agent safinamide [J]. Synthesis, 2014, 46: 1751—1756.
[7] Francesco L, Carmelida C, Leonardo P, et al. Solid-phase synthesis and insights into structure activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase [J]. J Med Chem, 2007, 50(20): 4909—4916.
[8] Salom C, Salom E, Stables JP, et al. Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities [J]. J Med Chem, 2010, 53(9): 3756—3771.
PDF(5479 KB)
